



SHUKRA

PHARMACEUTICALS LTD.

25th April, 2024

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: 524632

Dear Sir/Madam,

Sub: Outcome of the Board Meeting held on April 25,2024.

Ref: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 (read with Part A of Schedule III) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended, this is to inform you that the Board of Directors at its meeting held today i.e. April 25, 2024, has inter-alia, considered and approved the following items:

The Company has received approval from shareholders to issue bonus shares through postal ballot on April 03rd 2024 and the BSE In Principle approval received on 18th March, 2024 bearing letter no: LOD/Bonus/BN-IP/TT/1444/2023-24. The Board of Directors in their meeting held today has approved allotment of 3,28,40,958 shares having face value of Rs. 10/- (Rupees Ten Only) each in ratio of 3 (Three) new Equity shares for every 1 (One) Equity shares held by the shareholders as on record date i.e. 20th April, 2024.

The Board Meeting commenced at 05:30 PM and concluded at 06:05 PM.

Kindly place the same on your record


Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited


Arpita Kabra

Company secretary – Compliance officer
ACS No. – A50258



CIN : L24231GJ1993PLC019079